Patent EP0217341A2 successfully refreshed from Google Patents.
EP0217341A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
Assignee: Kowa Co Ltd
•
Filing: 1986-09-29
•
Granted: —
•
Expires: 2006-09-29
Abstract
Abstract Novel human placenta-derived anticoagulating substances having the following properties: (1) molecular weight of 34,000 ± 2,000 determined by SDS-polyacrylamide gel eiectrphoresis under reduced state; (2) isoelectric point of 4.7 ± 0.1 determined by isoelectric column electrophoresis using an ampholite; (3) stability inactive by heat treatment at 50°C for 30 minutes, stable at a pH of 4 - 10, and stable in plasma at 37°C for 30 minutes: (4) activity capable of prolonging a recalcification time, a prothrombin time, and an activated partial thromboplastin time; and (5) the existence of several amino acids including aspartic acid, threonine, serine, and so on; are prepared by homogenizing human placenta, subjecting the resulting homogenate to centrifugal separation, extracting an anticoagulating substance from the residue or from a microsome fraction contained in the supernatant with a surface active agent and/or a chelating agent, and purifying and isolating the substance from the extract. The anticoagulating substances have a high anticoagulating activity and exhibit a higher activity in the state where the tissue thromboplastin activity is exacerbated or in the state of exacerbating the coagulation. Hence, the anticoagulant containing the substance as an effective component has reduced side effects and is thus harmless.
Inventors
- 👤 Masahiro Maki
- 👤 Hideo Tani
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 21:46
CPC Classifications
A; A61; A61K; A61K35/00; A61K35/12; A61K35/48; A61K35/50; C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C07K14/4701; C07K14/4721; A61P; A61P7/00; A61P7/02; A61K38/00; G; G03; G03C; G03C1/00; G03C1/005; G03C1/04; G03C1/047; G03C2001/0471; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/842; Y10S530/85; Y10S530/851
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
9 words
A human placenta-derived anticoagulating substance having the following properties:
Claim 2
Dependent Claim
9 words
A human placenta-derived anticoagulating substance having the following properties:
Claim 3
Dependent Claim
11 words
(1) molecular weight (SDS-polyacrylamide gel electrophoresis, reduced state) 34,000 + 2,000;
Claim 4
Dependent Claim
11 words
(1) molecular weight (SDS-polyacrylamide gel electrophoresis, reduced state) 34,000 + 2,000;
Claim 5
Dependent Claim
12 words
(2) isoelectric point (isoelectric column electrophoresis using an ampholite) 4.7 + 0.1;
Claim 6
Dependent Claim
12 words
(2) isoelectric point (isoelectric column electrophoresis using an ampholite) 4.7 + 0.1;
Claim 7
Dependent Claim
30 words
(3) stability (a) inactivated by heat treatment at 50°C for 30 minutes, (b) stable at a pH of 4 - 10, (c) stable in plasma at 37°C for 30 minutes;
Claim 8
Dependent Claim
30 words
(3) stability (a) inactivated by heat treatment at 50°C for 30 minutes, (b) stable at a pH of 4 - 10, (c) stable in plasma at 37°C for 30 minutes;
Claim 9
Dependent Claim
26 words
(4) activity (a) capable of prolonging a recalcification time, (b) capable of prolonging a prothrombin time, (c) capable of prolonging an activated partial thromboplastin time; and
Claim 10
Dependent Claim
26 words
(4) activity (a) capable of prolonging a recalcification time, (b) capable of prolonging a prothrombin time, (c) capable of prolonging an activated partial thromboplastin time; and
Claim 11
Dependent Claim
37 words
(5) analysis of amino acids the existence of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, 1/2 cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine is recognized by the analysis of amino acids.
Claim 12
Dependent Claim
37 words
(5) analysis of amino acids the existence of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, 1/2 cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine is recognized by the analysis of amino acids.
Claim 13
Dependent Claim
179 words
A process for preparing a human placenta-derived anticoagulating substance having the following properties: (1) molecular weight (SDS-polyacrylamide gel electrophoresis, reduced state) 34,000 + 2,000; (2) isoelectric point (isoelectric column electrophoresis using an ampholite) 4.7 + 0.1; (3) stability (a) inactivated by heat treatment at 50°C for 30 minutes, (b) stable at a pH of 4 - 10, (c) stable in plasma at 37°C for 30 minutes; (4) activity (a) capable of prolonging a recalcification time, (b) capable of prolonging a prothrombin time, (c) capable of prolonging an activated partial thromboplastin time; and (5) analysis of amino acids the existence of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, 1/2 cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine is recognized by the analysis of amino acids, said process comprising the steps of homogenizing human placenta, subjecting the resulting homogenate to centrifugal separation, extracting an anticoagulating substance from the residue or from a microsome fraction contained in the supernatant with a surface active agent and/or a chelating agent, and purifying and isolating the substance from the extract.
Claim 14
Dependent Claim
179 words
A process for preparing a human placenta-derived anticoagulating substance having the following properties: (1) molecular weight (SDS-polyacrylamide gel electrophoresis, reduced state) 34,000 + 2,000; (2) isoelectric point (isoelectric column electrophoresis using an ampholite) 4.7 + 0.1; (3) stability (a) inactivated by heat treatment at 50°C for 30 minutes, (b) stable at a pH of 4 - 10, (c) stable in plasma at 37°C for 30 minutes; (4) activity (a) capable of prolonging a recalcification time, (b) capable of prolonging a prothrombin time, (c) capable of prolonging an activated partial thromboplastin time; and (5) analysis of amino acids the existence of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, 1/2 cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine is recognized by the analysis of amino acids, said process comprising the steps of homogenizing human placenta, subjecting the resulting homogenate to centrifugal separation, extracting an anticoagulating substance from the residue or from a microsome fraction contained in the supernatant with a surface active agent and/or a chelating agent, and purifying and isolating the substance from the extract.
Claim 15
Dependent Claim
131 words
An anticoagulant comprising an effective amount of a human placenta-derived anticoagulating substance having the following properties: (1) molecular weight (SDS-polyacrylamide gelelectrophoresis, reduced state) 34,000 + 2,000; (2) isoelectric point (isoelectric column electrophoresis using an ampholite) 4.7 + 0.1; (3) stability (a) deactivated by heat treatment at 50°C for 30 minutes, (b) stable at a pH of 4 - 10, (c) stable in plasma at 37°C for 30 minutes; (4) activity (a) capable of prolonging a recalcification, time, (b) capable of prolonging a prothrombin time, (c) capable of prolonging an activated partial thromboplastin time; and (5) analysis of amino acids the existence of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, 1/2 cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine is recognized by the analysis of amino acids.
Claim 16
Dependent Claim
131 words
An anticoagulant comprising an effective amount of a human placenta-derived anticoagulating substance having the following properties: (1) molecular weight (SDS-polyacrylamide gelelectrophoresis, reduced state) 34,000 + 2,000; (2) isoelectric point (isoelectric column electrophoresis using an ampholite) 4.7 + 0.1; (3) stability (a) deactivated by heat treatment at 50°C for 30 minutes, (b) stable at a pH of 4 - 10, (c) stable in plasma at 37°C for 30 minutes; (4) activity (a) capable of prolonging a recalcification, time, (b) capable of prolonging a prothrombin time, (c) capable of prolonging an activated partial thromboplastin time; and (5) analysis of amino acids the existence of aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, 1/2 cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, histidine, lysine and arginine is recognized by the analysis of amino acids.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.